Clinical Trials Logo
  1. Home
  2. Other
  3. NCT06089330

A Study of JMT101 in Patients With Metastatic Colorectal Cancer

Metastatic Colorectal Cancer (mCRC) Clinical Trial

Official title:
A Randomized, Controlled, Open-label Phase Ⅱ Study of The Safety, Tolerability and Efficacy of JMT101 and Irinotecan Combined With SG001 in Patients With Metastatic Colorectal Cancer (mCRC)

Clinical Trial Summary

This study is a phase Ⅱ, randomized, controlled, open-label, multi-center study with safety run-in to evaluate the efficacy and safety of JMT101 combined with Irinotecan and SG001 in Patients with Metastatic Colorectal Cancer (mCRC).

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06089330
Study type Interventional
Source Shanghai JMT-Bio Inc.
Contact Clinical Trials Information Group officer
Phone 86-0311-69085587
Email ctr-contact@cspc.cn
Status Not yet recruiting
Phase Phase 2
Start date January 2024
Completion date December 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02069704 - Bioequivalence Study Bevacizumab Biosimilar (BEVZ92) Versus Bevacizumab (AVASTIN®) in First-line Treatment mCRC Patients Phase 1
Recruiting NCT05286814 - M9241 in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer or Intrahepatic Cholangiocarcinoma Phase 2
Completed NCT01705002 - Intravenously Administered Pegylated Liposomal Mitomycin-C Lipid-based Prodrug (PROMITIL) in Cancer Patients With Solid Tumors. Phase 1
Completed NCT00594984 - Phase I/II Combination With Irinotecan- Erbitux Phase 1/Phase 2
Recruiting NCT03829462 - Assessing a Regorafenib-irinotecan Combination Versus Regorafenib Alone in Metastatic Colorectal Cancer Patients Phase 3
Recruiting NCT04856787 - A Clinical Studyf of SHR-1701 or Placebo in Combination With BP102 and XELOX in the First-line Treatment of mCRC Phase 2/Phase 3
Recruiting NCT05970302 - XELOX +Bev +Tislelizumab for First-line Treatment of MSS/pMMR RAS-mutated mCRC Phase 2
Completed NCT05420909 - A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC)
Active, not recruiting NCT02649790 - Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications Phase 1/Phase 2
Active, not recruiting NCT03511963 - A Clinical Study to Compare the Efficacy, Safety and Immunogenicity of HLX04 and Bevacizumab Combined XELOX or mFOLFOX6 in the First-line Treatment of mCRC Phase 3
Active, not recruiting NCT05839951 - An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions